These emerging therapies , Retatrutide, represent a remarkable advancement in treating metabolic dysfunction and possibly associated disorders. They are categorized as GLP-1 receptor agonists , https://reganrfsd346314.liberty-blog.com/41827683/retatrutide-a-thorough-dive-into-incretin-agents